Decibel Therapeutics Raises $82M to Advance Gene Therapies to Restore Hearing and Balance
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2M. The financing was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor…
Read MoreDecibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with…
Read MoreDecibel Therapeutics to Present New Findings at American Society of Gene & Cell Therapy Meeting
BOSTON, MASSACHUSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that it will present new findings on its pipeline and platform at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which will be held virtually from May 12–15. Decibel’s…
Read MoreDecibel Therapeutics Publishes Encouraging Results from Phase 1a Clinical Trial of DB-020
BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a development-stage biotechnology company developing novel regenerative therapeutics for hearing loss and balance disorders, announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs. DB-020 is being developed for the prevention of cisplatin-induced hearing…
Read More
Decibel Therapeutics Appoints New CEO; Announces Strategic Research Focus on Regenerative Medicine for Inner Ear
BOSTON, MASSACHUSSETTS — Biotech startup, Decibel Therapeutics, announced today that the company has appointed Laurence Reid, Ph.D., as acting chief executive officer, bringing extensive experience in biotech company building. According to the company announcement, CEO Steven Holtzman is retiring and will become a strategic business advisor to the company. As CEO, Dr. Reid brings experience in…
Read More
Healthcare Industry Veteran, Christine Poon, Appointed to Decibel Therapeutics Board of Directors
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Christine Poon to its board of directors. Ms. Poon has spent more than 30 years in leadership roles in the biopharmaceutical industry. She currently serves as executive in residence of The Max M. Fisher College of Business at The Ohio State University, having…
Read More
Decibel Therapeutics Appoints New Chief Medical Officer and COO
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…
Read MorePharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics
Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…
Read More
Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…
Read More
Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics
BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…
Read More